Our value creation is underpinned by good governance

Board committees’ current and future focus

Audit Committee

The role of the committee includes, but is not limited to, carrying out the responsibilities outlined in section 94 of the Companies Act as well as to assist the Board in the effective discharge of its responsibilities which includes the effectiveness of assurance functions and services as well as the integrity of reports issued.

Rob Theunissen
Chair: Audit Committee
Members
who served on HRRC over period ending 31 March 2021
  • A Ramalho
    (until 22 January 2021)
  • Prof W Gumede
    (retired 9 July 2020)
  • F Burn
  • G Leong
  • S Fakie
    (from 22 January 2021)
  • T Mokgatlha
    (from 16 April 2021)
Declaration


The Committee reports that for the year ended 31 March 2021, it is satisfied that it has fulfilled its responsibilities in accordance with the Companies Act, the Board Charter, the Committee Terms of Reference, King IV™ and other applicable standards and codes.
Background statement (Aligned to the amended terms of reference)
Key focus areas for the period under review (1 April 2020 to 31 March 2021)
Future focus areas of the Committee (1 April 2021 to 31 March 2022)
RISKS
CAPITALS
KING IVTM
STAKEHOLDERS

Human Resources and Remuneration Committee

The Committee has the task of ensuring that all Human Resource policies and practices are fair, competitive and in line with best practice and current legislation to enable the organisation to recruit and retain the best talent for optimal performance against its strategic objectives. The Committee also ensures that staff members are fairly and equitably remunerated for their contribution, both in respect of guaranteed and variable pay.

P Mthethwa
Chair: Human Resources and Remuneration Committee
Members
who served on HRRC over period ending 31 March 2021
  • P Mthethwa
    (Chair from 27 August 2020)
  • Prof W Gumede
    (Chair until 9 July 2020)
  • G Simelane
    (until 21 January 2021)
  • R Theunissen
  • G Leong (since 22 January 2021)
  • S Fakie
    (since 22 January 2021)
Declaration


The Committee has executed its responsibilities in accordance with an approved mandate.
Background statement (Aligned to the amended terms of reference)
Key focus areas of the Committee for the period under review (1 April 2020 to 31 March 2021)
Future focus areas of the Committee (1 April 2021 to 31 March 2022)
RISKS
CAPITALS
KING IVTM
STAKEHOLDERS

Clinical Governance Committee

The role of the Committee is to oversee the quality and safety of blood and blood products and the safety of donors, blood recipients and employees.

Dr Paddy Knox
Chair: Clinical Governance Committee
Members
who served on CGC over period ending 31 March 2021
  • Dr P Knox (Chair)
  • Prof V Moodley
    (resigned 1 July 2020)
  • F Burn
  • Dr Vaithilingum
    (appointed 1 July 2020)
  • Dr J Thomson (Medical Director
    resigned 27 February 2021)
  • Dr N Mashigo*
    (appointed 9 February 2021 )
  • M Toubkin*
    (ended her term 30 November 2020)
  • Prof A Rantloane*
  • Adv C Slump*

* Independent members of the Committee who are not members of the Board.

Declaration


The committee has executed its responsibilities in accordance with an approved mandate.
Background statement (Aligned to the amended terms of reference)
Key focus areas of the Committee for the period under review (1 April 2020 to 31 March 2021)
Future focus areas of the Committee (1 April 2021 to 31 March 2022)
RISKS
CAPITALS
KING IVTM
STAKEHOLDERS

Governance, Social and Ethics Committee

The role of the Committee is the oversight of, and reporting on Company ethics, responsible corporate citizenship, sustainable development and stakeholder relationships. This committee serves as the statutory social and ethics committee as required in terms of the Companies Act, 2008 and its duties are informed by regulation 43 of this Act. In addition, this committee has been charged by the Board to oversee corporate governance aspects that includes the assessment of the performance of the Board and compliance with the MoI and the rules of the Company.

Shauket Fakie
Chair: Governance, Social and Ethics Committee
Members
who served on GSE over period ending 31 March 2021
  • S Fakie
    (Chair appointed on 22 January 2021)
  • A Ramalho
    (Chair until 22 January 2021 )
  • G Simelane
    (until 21 January 2021)
  • Prof V Moodley
    (until 9 July 2020)
  • Dr M Vaithilingum
    (since 26 November 2020)
  • Dr J Louw
    (until 31 December 2020)
  • P Mthethwa
  • R Reddy
    (CEO since 1 January 2021)
  • B Damons
    (outside co-opted member)
Declaration


The committee has executed its responsibilities in accordance with a defined mandate.
Background statement (Aligned to the amended terms of reference)
Key focus areas of the Committee for the period under review (1 April 2020 to 31 March 2021)
Future focus areas of the Committee (1 April 2021 to 31 March 2022)
RISKS
CAPITALS
KING IVTM
STAKEHOLDERS
6

Nomination Committee

The role of the Committee is primarily to assist the Board with the recruitment of suitably qualified candidates as Non-Executive Board members; and to ascertain whether Board members up for re-election are to be re-appointed. The Committee leads the Board’s Non-Executive Director (NED) succession planning. Furthermore, the Committee supports the SANBS Board in the areas within its mandate.

ANSIE RAMALHO
Chair: Nomination Committee
Members
who served on NomCom over period ending 31 March 2021
  • Prof W Gumede
    (Chair until 9 July 2020)
  • A Ramalho
    (Chair from 22 January 2021)
  • G Simelane
    (until 21 January 2021)
  • Dr P Knox
  • R Theunissen
  • Dr M Vaithilingum
    (from 22 February 2021)
  • P Mthethwa
    (from 22 February 2021)
  • Dr K Letlape*
  • B Maasdorp*

* Independent members of the Committee who are not members of the Board until 1 December 2020

Declaration


The committee has executed its responsibilities in accordance with a defined mandate.
Background statement (Aligned to the amended terms of reference)
Key focus areas of the Committee for the period under review (1 April 2020 to 31 March 2021)
Future focus areas of the Committee (1 April 2021 to 31 March 2022)
RISKS
None
CAPITALS
KING IVTM
STAKEHOLDERS
-->

Risk, Technology and Information Governance Committee

The role of the Committee is to assist the Board with the governance of risk, technology and information. The Committee makes recommendations to the Board for its approval.

Faith Burn
Chair: Risk, Technology and Information Governance Committee
Members
who served on RTIG as at 31 March 2021
  • A Ramalho (Chair until appointment of F Burn)
  • F Burn (appointed as Chair from 11 February 2021)
  • Dr P Knox
  • G Leong
  • Dr J Louw (CEO until 31 December 2020)
  • Dr J Thomson (Medical Director resigned 27 February 2021)
  • R Ravi (CEO from 1 January 2021)

Note:Dr K van den Berg (Medical Director appointed 1 June 2021) replaces Dr J Thomson

Declaration


The committee has executed its responsibilities in accordance with a defined mandate
Background statement (Aligned to the amended terms of reference)
Key focus areas of the Committee for the period under review (1 April 20120 to 31 March 2021)
Future focus areas of the Committee (1 April 2021 to 31 March 2022)
RISKS
CAPITALS
KING IVTM
STAKEHOLDERS